Can Kaya pull off its ambitious makeover?

Summary: Kaya is attempting a bold reset—cutting weak clinics, revamping its model and chasing profitability in India’s fast-growing aesthetic dermatology market. With promoter backing and cleaner unit economics, it’s showing early promise, but the long road to corporate breakeven and talent risks make this a cautious watchlist story. India’s beauty and wellness market is heating up. From Hindustan Unilever snapping up Minimalist to Reliance launching Tira in 2023 and now the Birlas entering the fray with Birla Cosmetics, the big players are all-in. The market is attracting capital and investor attention alike. Amid all this glamour, Kaya occupies a quieter, more niche corner: dermatology and aesthetic skin services. A listed player in a space dominated by unlisted chains, Kaya has been loss-making for years. Yet it refuses to disappear, now attempting a comeback. The question is whether these moves can turn losses into growth or if Kaya is simply reshuffling the deck. From Marico’s experiment to becoming a loss-making venture Kaya began as Marico’s ambitious experiment: a dermatology-focused skincare chain backed by a heavyweight FMCG. In 2013, Kaya was demerged into a separately listed entity. The rationale was sound. A services-heavy business would operate more efficiently outside an FMCG balance sheet and raise capital on its own ter